Trial intelligence / Profile preview

Phase II study of MAX-40279 combined with VA regimen in newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy

CTR20250827Phase 2Active

Sponsor

Guangzhou Zaiji Medical Technology

Start

Sep 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1